January 25, 2021

Managing RET-Rearranged NSCLC With a Focus on Pralsetinib
Of the various types of non-small cell lung cancer (NSCLC), one of the most difficult to treat is Rearranged during Transfection (RET)-rearranged NSCLC. RET-rearrangement occurs in about 1% to 2% of adenocarcinoma NSCLC. Patients with this type of NSCLC are typically younger, female, and light or never smokers. Read more.


Myelodysplastic Syndrome and AML Associated With PARP Inhibitors
Over the past 7 years, four PARP (poly[ADP-ribose] polymerase) inhibitors, niraparib, olaparib, rucaparib, and talazoparib, have been approved in the United States and have led to clinically significant improvements in progression-free survival in patients with recurrent or primary ovarian cancer. However, recent data has come to light that warns of potentially serious adverse events associated with this class of medications. Read more.

Net Spending on Specialty Pharmaceuticals Surging 
Specialty pharmaceuticals are one of the fastest growing classes of medications in part due to rapidly rising drug prices, increased approval of biological agents, and medications that require specialized handling or administration techniques, and a focus on costly drugs to treat orphan conditions and/or complex conditions. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App